Holen Sie sich die Stockscreener-App
899.72
4.22%
36.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$862.86
Offen:
$866.53
24-Stunden-Volumen:
3.38M
Relative Volume:
0.76
Marktkapitalisierung:
$851.56B
Einnahmen:
$59.42B
Nettoeinkommen (Verlust:
$18.41B
KGV:
44.50
EPS:
20.2197
Netto-Cashflow:
$-50.20M
1W Leistung:
+8.82%
1M Leistung:
+7.07%
6M Leistung:
+9.19%
1J Leistung:
+9.81%
1-Tages-Spanne:
$862.62
$899.83
1-Wochen-Bereich:
$809.63
$899.30
52-Wochen-Spanne:
$623.78
$935.62
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
899.73 | 772.28B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
186.81 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
212.87 | 385.18B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.31 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.34 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly to invest €2.7 billion in new factory near Leiden - DutchNews.nl
Lilly Announces $1.2B Puerto Rico Expansion, Adding 100 Jobs - InkFreeNews.com
Lilly to build $3 billion Dutch plant to boost weight-loss pill production - Reuters
Eli Lilly’s New Study on Brenipatide: A Potential Game-Changer in Smoking Cessation - TipRanks
Lilly Reveals Plan for New $3 Billion Manufacturing Facility in the Netherlands - Pharmaceutical Commerce
Eli Lilly Starting to Tap Into International GLP-1 Demand -- Market Talk - 富途牛牛
$3 Billion Netherlands Plant Part of Lilly’s Global Weight-Loss Push - WIBC 93.1 FM
Eli Lilly building new $3 billion manufacturing facility in Netherlands - WTHR
Eli Lilly (LLY) Invests $3B in Dutch Facility for Obesity Drug P - GuruFocus
Eli Lilly: $3bn investment in new plant in Netherlands - MarketScreener
Lilly's global manufacturing blitz rolls on with $3B plant in Netherlands, plans for 500 hires - Fierce Pharma
Eli Lilly (LLY) to Invest $3 Billion in Dutch Manufacturing Faci - GuruFocus
Lilly to build $3 billion plant in the Netherlands to boost weight-loss pill production - Latest news from Azerbaijan
Lilly to build $3 billion oral medicine facility in Netherlands - Investing.com
Eli Lilly to build new $3 billion manufacturing facility in Katwijk, the Netherlands - MarketScreener
Eli Lilly Plans to Construct $3 Billion Production Site in Katwijk, Netherlands - MarketScreener
Lilly to build $3B production facility in Netherlands - breakingthenews.net
Eli Lilly to build new $3B facility in Katwijk, the Netherlands - TipRanks
Bernstein reiterates Eli Lilly stock rating at Outperform after strong Q3 - Investing.com Nigeria
Eli Lilly to build $3B manufacturing site in Netherlands - Indianapolis Business Journal
2 Healthcare Stocks for Individual Investors With a 30-Year Time Horizon - The Motley Fool
Uline, Eli Lilly strive to build talent in Racine, Kenosha area - The Business Journals
HSBC Adjusts Price Target on Eli Lilly and Co. to $850 From $800, Maintains Hold Rating - MarketScreener
Prediction: The Next Eli Lilly Might Already Be Trading Under $50 - AOL.com
Eli Lilly’s Meteoric Rise Fueled by Blockbuster Drugs - AD HOC NEWS
Jim Cramer Admits Surprise at Eli Lilly’s Rally After Strong GLP-1 Results - MSN
Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback - MSN
Eli Lilly (LLY) Surges on Strong Q3 Results and Upgraded 2025 Ou - GuruFocus
Why The Story Around Eli Lilly Is Evolving After Recent Analyst Updates and Company News - Yahoo! Finance UK
Eli Lilly and Company Beat Revenue Forecasts By 9.5%: Here's What Analysts Are Forecasting Next - Yahoo Finance
Eli Lilly and Company $LLY Shares Acquired by Tredje AP fonden - MarketBeat
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push - ETPharma.com
A Look at Eli Lilly’s (LLY) Valuation After Strong Q3 Earnings, Upbeat Guidance, and Zepbound Expansion Plans - simplywall.st
Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer - MSN
Eli Lilly To Invest Over $1.2 Billion In Puerto Rico Expansion To Boost U.S. Oral Medicine Manufacturing - Pulse 2.0
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $976 to $1,069 - 富途牛牛
Why Eli Lilly Stock Rose Almost 5% Last Week? - TIKR.com
S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points - Investor's Business Daily
Eli Lilly Reports Strong Q3 2025 Growth - The Globe and Mail
Eli Lilly’s Earnings Call: Robust Growth and Strategic Wins - TipRanks
AstraZeneca, Eli Lilly, Merck commit $120M to Virginia pharma training - Virginia Business
Eli Lilly and Company (NYSE:LLY) Trading 2.2% Higher on Strong Earnings - MarketBeat
Evaluating Eli Lilly (LLY): Is the Pharma Giant’s Recent Growth Reflected in Its Current Valuation? - Yahoo Finance
Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval - TipRanks
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report - Pharmaceutical Executive
IU-Lilly study to explore drugs’ impact on job productivity - Indianapolis Business Journal
Argus Raises Eli Lilly's Price Target to $930 From $900 - MarketScreener
Why Eli Lilly is making weight-loss pills before regulatory approval - Yahoo! Finance UK
Eli Lilly's Diabetes, Obesity Drugs Drive Strong Q3 Beat, BofA Securities Says - MarketScreener
Eli Lilly’s Weight-Loss Drugs Set New Sales Records - Finimize
Lilly quietly cuts a pain drug from its pipeline - BioPharma Dive
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):